
    
      Five patients who are on treatment of imatinib and deriving clinical benefit after
      CAMN107DBR01 study termination and written informed consent obtained will enter the trial,
      all five patients will receive Glivec (8oomg per day) treatment until tumor progression [by
      RECIST guidelines, version 1.0], unacceptable toxicity, death or withdrawal of consent.
    
  